Ernexa Therapeutics Inc. Research and Development Expense
Ernexa Therapeutics Inc. (ERNA) reported Research and Development Expense of $1.69 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-11
- Ernexa Therapeutics Inc. research and development expense for the quarter ending 2022-06-30 was $1.69M, a 68.98% decline year-over-year.
- Ernexa Therapeutics Inc. research and development expense for the quarter ending 2022-03-31 was $1.78M, a 16.24% increase year-over-year.
- Ernexa Therapeutics Inc. research and development expense for the quarter ending 2021-06-30 was $5.43M.
- Ernexa Therapeutics Inc. research and development expense for the quarter ending 2021-03-31 was $1.53M.
- Ernexa Therapeutics Inc. research and development expense for fiscal 2020 was $2.00K, a 92.31% decline from fiscal 2019.
- Ernexa Therapeutics Inc. research and development expense for fiscal 2019 was $26.00K, a 63.89% decline from fiscal 2018.
- Ernexa Therapeutics Inc. research and development expense for fiscal 2018 was $72.00K, a 48.20% decline from fiscal 2017.
- Ernexa Therapeutics Inc. research and development expense for fiscal 2017 was $139.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2022-06-30 | $1.69M 10-Q · filed 2022-08-11 | $3.47M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $1.78M 10-Q · filed 2022-07-01 | ||||
| 2021-06-30 | $5.43M 10-Q · filed 2022-08-11 | $5.39M 10-Q · filed 2021-08-13 | $6.96M 10-Q · filed 2022-08-11 | $6.91M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $1.53M 10-Q · filed 2022-07-01 | $1.52M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $2.00K 10-K · filed 2021-03-11 | ||||
| 2019-12-31 | $26.00K 10-K · filed 2021-03-11 | ||||
| 2018-12-31 | $72.00K 10-K · filed 2020-03-19 | ||||
| 2017-12-31 | $139.00K 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |